trending Market Intelligence /marketintelligence/en/news-insights/trending/65ui-SA8X5Z-QgpI_Vu_Uw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Eli Lilly breast cancer drug gets US FDA priority review stamp

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Eli Lilly breast cancer drug gets US FDA priority review stamp

Eli Lilly & Co. said the U.S. Food and Drug Administration granted priority review designation for its new drug application for Verzenio to treat breast cancer.

The application was based on the positive interim results of the MONARCH 3 study on Verzenio, or abemaciclib, combined with an aromatase inhibitor as initial endocrine-based therapy for treating women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

Lilly had completed the EU and Japan regulatory submissions for the drug during the third quarter.

About 252,710 new cases of invasive breast cancer are expected to be diagnosed in the U.S. in women in 2017.